SG11201807038UA - Rodents having a humanized tmprss gene - Google Patents

Rodents having a humanized tmprss gene

Info

Publication number
SG11201807038UA
SG11201807038UA SG11201807038UA SG11201807038UA SG11201807038UA SG 11201807038U A SG11201807038U A SG 11201807038UA SG 11201807038U A SG11201807038U A SG 11201807038UA SG 11201807038U A SG11201807038U A SG 11201807038UA SG 11201807038U A SG11201807038U A SG 11201807038UA
Authority
SG
Singapore
Prior art keywords
international
new york
tarrytown
rule
rodents
Prior art date
Application number
SG11201807038UA
Inventor
Ngambo Lisa Purcell
Alexander O Mujica
Yajun Tang
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11201807038UA publication Critical patent/SG11201807038UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization IIIMI41101110101011111 HO 11111011101 Ell 01011111101100111110 1111 III International Bureau 0.. .... .. (10) International Publication Number ..... ...,/ (43) International Publication Date WO 2017/151453 Al 8 September 2017 (08.09.2017) WIP0 I PCT (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, AO1K 67/027 (2006.01) Cl 2N 9/64 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, PCT/US2017/019574 KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (22) International Filing Date: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, 27 February 2017 (27.02.2017) NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (25) Filing Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (26) Publication Language: English ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 62/301,023 29 February 2016 (29.02.2016) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: REGENERON PHARMACEUTICALS, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, New York 10591-6707 (US). DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (72) L Inventors: PURCELL NGAMBO, Lisa; c/o Regeneron V, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Pharmaceuticals, Inc., 777 Old Saw Mill River Road, GW, KM, ML, MR, NE, SN, TD, TG). Tarrytown, New York 10591-6707 (US). MUJICA, Alex- ander 0.; c/o Regeneron Pharmaceuticals, Inc., 777 Old Declarations under Rule 4.17: Saw Mill River Road, Tarrytown, New York 10591-6707 — as to applicant's entitlement to apply for and be a granted (US). TANG, Yajun; c/o Regeneron Pharmaceuticals, patent (Rule 4.17(ii)) Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591-6707 (US). — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Agent: GROLZ, Edward W.; Scully, Scott, Murphy & (74) Presser, 400 Garden City Plaza, Suite 300, Garden City, Published: New York 11530 (US). — with international search report (Art. 21(3)) Designated States (unless otherwise indicated, for every _ with sequence listing part of description (Rule 5.2(a)) kind of national protection available): AE, AG, AL, AM, (81) Il M kir) 71- 1-1 kir) 1-1 IN 1-1 © (54) ei Title: RODENTS HAVING A HUMANIZED TMPRSS GENE 0 (57) : Genetically modified rodents such as mice and rats, and methods and compositions for making and using the same, are provided. The rodents comprise a humanization of at least one endogenous rodent Tmprss gene, such as an endogenous rodent Tmprss2, Tmprss4, or Tmprss 1 1 d gene.
SG11201807038UA 2016-02-29 2017-02-27 Rodents having a humanized tmprss gene SG11201807038UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662301023P 2016-02-29 2016-02-29
PCT/US2017/019574 WO2017151453A1 (en) 2016-02-29 2017-02-27 Rodents having a humanized tmprss gene

Publications (1)

Publication Number Publication Date
SG11201807038UA true SG11201807038UA (en) 2018-09-27

Family

ID=58264641

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201807038UA SG11201807038UA (en) 2016-02-29 2017-02-27 Rodents having a humanized tmprss gene
SG10202001578RA SG10202001578RA (en) 2016-02-29 2017-02-27 Rodents having a humanized tmprss gene

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202001578RA SG10202001578RA (en) 2016-02-29 2017-02-27 Rodents having a humanized tmprss gene

Country Status (14)

Country Link
US (4) US10070632B2 (en)
EP (2) EP3422845B1 (en)
JP (1) JP6980674B2 (en)
KR (2) KR20230021759A (en)
CN (1) CN109068621B (en)
AU (1) AU2017228293B2 (en)
CA (1) CA3014645C (en)
DK (1) DK3422845T3 (en)
ES (1) ES2886958T3 (en)
IL (1) IL261139B (en)
PT (1) PT3422845T (en)
RU (1) RU2749715C2 (en)
SG (2) SG11201807038UA (en)
WO (1) WO2017151453A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3422845T (en) 2016-02-29 2021-08-26 Regeneron Pharma Rodents having a humanized tmprss gene
CN111163633B (en) * 2017-09-29 2022-09-09 瑞泽恩制药公司 Non-human animals comprising humanized TTR loci and methods of use thereof
LT3638698T (en) 2018-01-26 2021-04-12 Regeneron Pharmaceuticals, Inc. Anti-tmprss2 antibodies and antigen-binding fragments
CN116200426A (en) 2018-07-16 2023-06-02 瑞泽恩制药公司 Non-human animal model of DITRA disease and uses thereof
EP3911154A1 (en) 2019-01-17 2021-11-24 Regeneron Pharmaceuticals, Inc. A rodent model of mood disorders
CA3163164A1 (en) 2020-02-10 2021-08-19 Alina Baum Anti-tmprss2 antibodies and antigen-binding fragments
CN115161326A (en) * 2021-06-21 2022-10-11 百奥赛图(北京)医药科技股份有限公司 SOST gene humanized non-human animal and construction method and application thereof
WO2023122506A1 (en) * 2021-12-20 2023-06-29 Regeneron Pharmaceuticals, Inc. Non-human animals comprising humanized ace2 and tmprss loci

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002065266A (en) * 2000-08-28 2002-03-05 Teijin Ltd Airway-specific trypsin-like enzyme and method for utilizing the same
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1469717A4 (en) * 2001-12-20 2007-08-22 Univ California Triple transgenic mouse model of alzheimer's disease
US20050026255A1 (en) * 2002-06-25 2005-02-03 Morser John Michael Corin, a serine protease
WO2004033630A2 (en) * 2002-10-04 2004-04-22 Schering Aktiengesellschaft Modified hepsin molecules having a substitute activation sequence and uses thereof
CN101109011A (en) * 2003-06-11 2008-01-23 舍林股份公司 Novel modified corin molecules having substitute activation sequences and uses thereof
US7491865B2 (en) * 2004-08-19 2009-02-17 Fred Hutchinson Cancer Research Center Mouse models of prostate cancer development and metastasis through expression of a hepsin transgene
CA2827654C (en) 2004-10-19 2019-04-02 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
RU2419625C2 (en) * 2006-05-23 2011-05-27 Айрм Ллк Compounds and compositions as canal activating protease inhibitors
GB0821624D0 (en) * 2008-11-26 2008-12-31 Eisai London Res Lab Ltd Assay
RU2636046C2 (en) * 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Modified antibodies composition, methods of production and application
RU2425880C2 (en) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Method of producing transgene mice
ES2591107T3 (en) 2009-10-06 2016-11-24 Regeneron Pharmaceuticals, Inc. Genetically modified mice and graft
RU2730643C2 (en) 2011-02-15 2020-08-24 Ридженерон Фармасьютикалз, Инк. Humanised m-csf mice
LT3590332T (en) 2011-10-28 2022-08-10 Regeneron Pharmaceuticals, Inc. Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules
CN107254480B (en) 2011-10-28 2021-08-10 瑞泽恩制药公司 Method for preparing major histocompatibility complex gene modified mouse
DK2818478T3 (en) 2011-10-28 2017-05-22 Regeneron Pharma HUMANIZED IL-6 AND IL-6 RECEPTOR
CA3219083A1 (en) * 2012-04-16 2013-10-24 Regeneron Pharamaceuticals, Inc. Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor
US8962913B2 (en) 2012-06-18 2015-02-24 Regeneron Pharmaceuticals, Inc. Humanized IL-7 rodents
AU2013278075B2 (en) * 2012-06-22 2018-05-17 Cytomx Therapeutics, Inc. Anti-jagged 1/Jagged 2 cross-reactive antibodies, activatable anti-Jagged antibodies and methods of use thereof
KR102594390B1 (en) 2012-09-07 2023-10-27 예일 유니버시티 Genetically modified non-human animals and methods of use thereof
CN104918483B (en) 2012-11-05 2018-05-11 再生元制药公司 Generation and the method using genetically modified non-human animal
SI2958938T1 (en) 2013-02-20 2019-08-30 Regeneron Pharmaceuticals, Inc. Mice expressing humanized t-cell co-receptors
WO2014130706A1 (en) 2013-02-20 2014-08-28 Regeneron Pharmaceuticals, Inc. Genetic modification of rats
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
CN105164154B (en) 2013-02-22 2019-06-07 瑞泽恩制药公司 Express the mouse of humanization major histocompatibility complex
LT3456831T (en) 2013-04-16 2021-09-10 Regeneron Pharmaceuticals, Inc. Targeted modification of rat genome
US9517276B2 (en) * 2013-06-04 2016-12-13 Cytomx Therapeutics, Inc. Compositions and methods for conjugating activatable antibodies
TR201901782T4 (en) 2013-09-23 2019-03-21 Regeneron Pharma NON-HUMAN ANIMALS WITH A HUMANIZED SIGNAL REGULATOR PROTEIN GENE.
MX2016004781A (en) 2013-10-15 2016-07-26 Regeneron Pharma Humanized il-15 animals.
CA2929846C (en) 2013-11-19 2020-09-15 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
JP6484237B2 (en) 2013-11-19 2019-03-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Non-human animals having humanized growth-inducing ligand genes
DK3129400T3 (en) 2014-04-08 2020-06-08 Regeneron Pharma Non-human animals with humanized Fc-gamma receptors
NO2785538T3 (en) 2014-05-07 2018-08-04
ES2964597T3 (en) 2014-05-19 2024-04-08 Regeneron Pharma Genetically modified mice that express human EPO
BR112016029650A2 (en) 2014-06-19 2017-10-24 Regeneron Pharma rodent, pd-1 polypeptide, isolated cell or rodent tissue, rodent embryonic stem cell, methods of producing a rodent, reducing tumor growth in a rodent, killing tumor cells in a rodent, and evaluating pharmacokinetic properties of a drug that targets human pd-1, and, rodent tumor model?
AU2015353705C9 (en) 2014-11-24 2022-09-01 Regeneron Pharmaceuticals, Inc. Non-human animals expressing humanized CD3 complex
DK3466255T3 (en) 2014-12-05 2021-05-03 Regeneron Pharma NON-HUMAN ANIMALS WITH A HUMANIZED CLUSTER OF 47-GENE DIFFERENTIATION
AU2015360667B2 (en) 2014-12-09 2021-09-23 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 274 gene
BR112017021250A2 (en) 2015-04-06 2018-06-26 Regeneron Pharma humanized t-cell mediated immune responses in non-human animals
AU2016358101B2 (en) 2015-11-20 2022-12-01 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized Lymphocyte-activation gene 3
PT3422845T (en) 2016-02-29 2021-08-26 Regeneron Pharma Rodents having a humanized tmprss gene
KR101693243B1 (en) 2016-06-15 2017-01-05 재단법인 한국파스퇴르연구소 Novel human gene crucial for the replication of influenza virus and use thereof

Also Published As

Publication number Publication date
EP3422845B1 (en) 2021-06-02
CN109068621B (en) 2021-07-20
DK3422845T3 (en) 2021-08-30
US10070632B2 (en) 2018-09-11
US20170245482A1 (en) 2017-08-31
ES2886958T3 (en) 2021-12-21
SG10202001578RA (en) 2020-04-29
CN109068621A (en) 2018-12-21
CA3014645A1 (en) 2017-09-08
EP3422845A1 (en) 2019-01-09
JP6980674B2 (en) 2021-12-15
RU2749715C2 (en) 2021-06-16
US20210068377A1 (en) 2021-03-11
IL261139B (en) 2022-04-01
US20170290308A1 (en) 2017-10-12
KR20230021759A (en) 2023-02-14
US10863729B2 (en) 2020-12-15
KR20180117122A (en) 2018-10-26
US20180332831A1 (en) 2018-11-22
US11910787B2 (en) 2024-02-27
AU2017228293A1 (en) 2018-08-23
WO2017151453A1 (en) 2017-09-08
RU2018131152A3 (en) 2020-07-13
IL261139A (en) 2018-10-31
JP2019511918A (en) 2019-05-09
EP3895529A1 (en) 2021-10-20
US10070631B2 (en) 2018-09-11
KR102493894B1 (en) 2023-01-31
RU2018131152A (en) 2020-04-01
CA3014645C (en) 2022-10-25
PT3422845T (en) 2021-08-26
AU2017228293B2 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
SG11201807038UA (en) Rodents having a humanized tmprss gene
SG11201810331YA (en) Single chain variable fragment cd3 binding proteins
SG11201900138TA (en) Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
SG11201909941QA (en) Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201806624XA (en) Deposition of molybdenum thin films using a molybdenum carbonyl precursor
SG11201807187XA (en) Binding members to pd-l1
SG11201810757YA (en) Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
SG11201810327XA (en) Single domain serum albumin binding protein
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201909160WA (en) Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
SG11201909203WA (en) Tissue selective transgene expression
SG11201907753TA (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201807881VA (en) Compositions and methods for making antibodies based on use of an expression-enhancing locus
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201901834WA (en) Micrornas as biomarkers for endometriosis
SG11201810003UA (en) Using programmable dna binding proteins to enhance targeted genome modification
SG11201906192SA (en) Methods of treating cancer with anti-pd-1 antibodies
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201808912QA (en) Targeted nucleic acid conjugate compositions
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201807885PA (en) Compositions and methods for making antibodies based on use of expression-enhancing loci
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201908456VA (en) Linker units and molecular constructs comprising same
SG11201805001UA (en) Method of treating influenza a